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Abstract
Background: The soluble transferrin receptor (sTfR) is
established as a test for iron deficiency (ID). In chronic
lymphocytic leukemia (CLL), sTfR is not reliable for
screening for ID as the latter is strongly dependent on
tumor burden.
Methods: We investigated whether the influence of
the tumor load can be excluded or minimized using
the sTfR/log ferritin ratio (TfR-F-Index) and the C-reac-
tive protein (CRP)-adjusted TfR-F-Index in 87 patients
with CLL. sTfR was measured nephelometrically (nor-
mal: 0.81–1.75 mg/L). A cut-off value of 1.5 for the
TfR-F-Index and 0.8 for the CRP-adjusted TfR-F-Index,
in patients with a CRP )5 mg/L, was used.
Results: All Binet A patients had normal sTfR values
(1.34"0.2 mg/L), TfR-F-Index (0.67"0.2) and a CRP-
adjusted TfR-F-Index. In Binet B and C, sTfR and the
TfR-F-Index were significantly increased compared to
Binet A patients (p-0.0001). The differences between
Binet B and C were not significant. sTfR was increased
in 85%, TfR-F-Index in 46% and the CRP-adjusted TfR-
F-Index in 54% of the Binet B patients, in Binet C
patients, 80%, 50% and 60% showed increases,
respectively. sTfR and the TfR-F-Index decreased or
even normalized following successful treatment.
Conclusions: Similar to sTfR, the TfR-F-Index is
strongly associated with tumor burden in patients
with CLL. Thus, these parameters do not allow for a
reliable diagnosis of ID in this patient group.
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Introduction
Iron deficiency (ID) represents the most common defi-
ciency disease in human beings, and constitutes one
of the main factors for anemia in malignancy (1). The
clinical diagnosis of ID is based primarily on labora-
tory parameters, particularly the standard tests for
ferritin, transferrin saturation and red cell indices.
Recently, newer tests for ID have been established,
including measurement of the percentage of hypo-
chromic erythrocytes (HYPO), reticulocyte hemoglo-
bin (CHr), erythrocytic zinc protoporphyrin (ZPP) and
serum concentrations of the soluble transferrin recep-
tor (sTfR). These tests are of particular clinical interest
as they directly reflect iron supply for erythropoiesis
(2–6). sTfR has a significant status within this series
of tests because real and functional ID in anemia of
chronic disorders can be reliably distinguished (2, 3).
However, the diagnostic importance of sTfR as a
screening parameter for ID is lessened by the fact that
sTfR concentrations are also dependent on erythro-
poietic activity (2). It is increased not only in ID, but
also in diseases with increased erythropoesis (2, 7, 8).
The use of sTfR in lymphoproliferative disorders is
particularly tricky, especially in patients with chronic
lymphocytic leukemia (CLL). A recent publication sug-
gested that sTfR does not reflect transferrin receptor
density on tumor cells but rather indicates tumor
burden in this patient group (9). Independently of iron
status and erythropoetic activity, sTfR values are sig-
nificantly increased in individuals with large tumor
mass, and normalize following successful treatment
(9).
To increase the diagnostic sensitivity and specificity
for sTfR in detecting ID, the sTfR/log ferritin ratio (TfR-
F-Index), the ratio of serum concentration of sTfR
(mg/L) and logarithm of the serum ferritin value
(mg/L), was introduced (3, 7, 10–13). In comparison to
single measurements of sTfR concentrations, the
combination of these two parameters as an indica-
tor of iron stores is considered to be more valuable
(3, 12). Further diagnostic improvement has been
attributed to determination of the C-reactive protein
(CRP)-adjusted TfR-F-Index (3, 7, 10–13), where the influ-
ence of inflammation on the acute phase reactant fer-
ritin is corrected by CRP (4). With normal CRP values,
a TfR-F-Index )1.5 defines ID, while for CRP values
)5 mg/L, a cut-off value of )0.8 is considered to be
suggestive of ID (4).
The goal of the present study was to investigate
whether the diagnostic improvement of sTfR achieved
by calculation of the TfR-F-Index and the CRP-adjust-
ed TfR-F-Index, is applicable in patients with CLL, and
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in particular if the influence of tumor load can be min-
imized or even excluded.
Patients and methods
The study was performed between 2000 and 2008 in the III.
Medizinischen Klinik, Universitätsmedizin Mannheim of the
University of Heidelberg. Only previously untreated patients
with CLL were enrolled and studied. Twelve of these patients
received fludarabine-based therapy and were monitored reg-
ularly. The diagnosis was based on the National Cancer Insti-
tute Criteria (14), including immunophenotyping and bone
marrow examination. All patients were staged according to
the Binet classification (Table 1) (15). Patients with ID (ns16),
hemolysis and autoimmune thrombocytopenia (ns11) were
excluded. In all cases, the presence of ID was excluded by
Prussian blue staining of the bone marrow and measure-
ment of ferritin (-35 mg/L for males, -25 mg/L for females).
In addition to determination of serum concentrations of
the sTfR, ferritin and the TfR-F-Index, we also obtained com-
plete blood counts including hemoglobin (Hb), platelet
counts, white blood cell (WBC) counts and differential
counts, as well as further parameters of hemolysis, such as
reticulocyte numbers, Coombs-test, haptoglobin, bilirubin
and lactate dehydrogenase (LDH) were determined at base-
line, and then at regular intervals during the course of the
study. In Binet C patients, autoimmune thrombocytopenia
was excluded by the determination of platelet associated
autoantibodies and bone marrow examination. The meas-
urements of Hb (reference ranges: 130–170 g/L for men,
120–160 g/L for women), mean corpuscular volume (MCV)
(reference range: 80–96 fL), WBC (reference range: 4.2–
10.2=109/L) and platelet counts (reference ranges: 145–
348=109/L for men, 165–387=109/L for women) were per-
formed using an automated cell counter (Model CC-180; Sys-
mex, Kobe, Japan). Serum ferritin (normal value: 35–310
mg/L for men, 25–210 mg/L for women) was measured using
the Access Ferritin immunoassay (Beckman-Coulter, Krefeld,
Germany), haptoglobin (normal value: 0.3–2.0 g/L) by the
Haptoglobin-Kit (Sentinel Diagnostics, Milan, Italy), bilirubin
(normal value: 2–21 mmol/L) and LDH (normal value:
0–248 U/L) were measured with a multi-analysis instrument
(SMAC II, Technicon, Tarrytown, NY, USA). Measurement of
sTfR (normal range: 0.81–1.75 mg/L) was performed using
the latex enhanced N Latex sTfR assay (Dade Behring, Mar-
burg, Germany). The TfR-F-Index was calculated as the ratio
of sTfR (mg/L) to the logarithm of ferritin (mg/L) (normal:
-1.5). For the CRP-adjusted TfR-F-Index, CRP was measured
using a turbidimetric high sensitivity assay (Dimension RxL,
Fa. Siemens; normal range: 0–5 mg/L). For normal CRP
concentrations, a TfR-F-Index )1.5 defines ID, for CRP )5
mg/L, a cut-off of )0.8 was used, as proposed by Thomas
and Thomas (4).
Data obtained in our previous study on 43 healthy individ-
uals without ID (mean sTfR: 1.18 mg/L"0.2, range 0.91–1.71;
TfR-F-Index: 0.57"0.12, range 0.41–0.92) were used as a
reference for the statistical analysis (16).
To exclude chemotherapy-related effects on erythropoe-
sis, sTfR, ferritin and the TfR-F-Index, the determination of
these parameters were performed 2–4 weeks after the last
course of therapy.
Tumor load was assessed in all patients at baseline and
then regularly during the course of the study by sonography,
evaluating the number of involved lymph node regions and
lymph node size. For statistical analysis, the maximal
longitudinal diameter of the largest lymph node measured
by sonography (Philips iU22, DA Best, Netherlands) was
used.
Statistical analyses were performed using GraphPad Prism
statistical package for Windows (Version 4.0, GraphPad
Software Inc, San Diego, CA, USA). The non-parametric
two-tailed Mann-Whitney test was used to determine signif-
icances between groups. Differences between frequencies
were evaluated for significance using the x2-test. A p-0.05
was considered for statistical significance.
Ethics
The study was conducted in accordance with the Declaration
of Helsinki 1975, as revised in 1983, and approved by the
Institutional Review Board. The study did not influence in
any way the management of patients, as all the tests used
in the study, including bone marrow examination, are rou-
tinely performed in all patients with CLL at the time of initial
presentation. All patients gave written informed consent.
Results
We enrolled 87 untreated patients with CLL (51 males,
36 females; median age 66 years, range 28–88 years)
into the study. The laboratory data obtained from
these patients, subdivided according to their Binet
stage, are summarized in Table 1. The individual TfR-
F-Index for all participants, subdivided according to
Binet, are depicted in Figure 1.
Thirty-eight participants (22 males, 16 females;
median age 68 years, range 39–87 years) were clas-
sified as Binet A. All Binet A patients showed normal
sTfR concentrations (mean sTfR 1.34"0.2 mg/L, range
0.71–1.75), TfR-F-Index (0.67"0.2, range 0.29–1.06)
and a CRP-adjusted TfR-F-Index (Table 1). When com-
pared to the healthy reference group without ID (16),
both the mean sTfR (p-0.0001) and the mean TfR-F-
Index (ps0.017) were significantly increased.
Thirty-nine patients (23 males, 16 females, median
age 72 years, range 28–86 years) were staged as Binet
B. The WBC counts were significantly higher (ps0.02)
and the mean lymph node size was significantly
greater (p-0.005) than in Binet A individuals (Table
1).
The mean sTfR concentration in Binet B patients
was significantly higher when compared to Binet A
patients (3.16"1.7 mg/L, range 1.3–9.5; p-0.0001).
The sTfR concentration was increased in 33 (85%) of
Binet B patients.
Calculating the TfR-F-Index in the Binet B group, the
values were significantly higher when compared to
the Binet A individuals (1.57"0.8, range 0.43–4.71;
p-0.0001). Normal values were observed in 21 of the
Binet B patients; in 18 individuals (46%), the TfR-F-
Index was greater than the cut-off value of 1.5. The
CRP-adjusted TfR-F-Index was increased in 21 (54%)
Binet B patients.
Ten patients (7 males, 3 females, median age
64 years, range 46–80 years) were classified as Binet
C. The mean WBC count and the mean maximal
lymph node size were significantly higher compared
to Binet A (ps0.02). However, there was no signifi-
cant difference in these parameters when comparing
Binet B and C individuals (Table 1).
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Table 1 Characteristics of all the participants, subdivided according to Binet stage.
Classification criteria Binet A Binet B Binet C
Lymphadenopathy -3 regions G3 regions Irrelevant
Hb, g/L )100 )100 F100
Platelet count, =109/L Normal Normal -100
Results
n (men/women) 38 (22/16) 39 (23/16) 10 (7/3)
WBC
w4.2–10.2=109/Lx 21.8"19.6 43.3"44.1 49.8"30.2
(6.2–133.0) (3.5–207) (10.5–99.9)
{A vs. B, 0.02} {B vs. C, n.s.}
Hb
wMen: 130–170 g/Lx 139"10.2 133"14.3 126"15.0
wWomen: 120–160 g/Lx (115–195) (104–163) (92–144)
{A vs. B, n.s.} {B vs. C, n.s.}
Platelet count
wMen: 145–348=109/Lx 222"65 190"55 81"10
wWomen: 165–387=109/Lx (123–457) (108–325) (70–95)
{A vs. B, n.s.} {B vs. C, 0.0001}
Reticulocyte count
w5–15‰x 11"6 12"6 12"5
(1–18) (4–17) (7–18)
{A vs. B, n.s.} {B vs. C, n.s.}
Ferritin
wMen: 35–310 mg/Lx 156"143 160"194 76"54
wWomen: 25–210 mg/Lx (25–728) (25–1160) (25–187)
{A vs. B, n.s.} {B vs. C, n.s.}
Lymph node sizea, cm 1.4"0.5 3.9"1.9 2.8"1.4
(0.7–3.0) (1.6–9.0) (1.0–5.8)
{A vs. B, -0.005} {B vs. C, n.s.}
sTfR
w0.81–1.75 mg/Lx 1.34"0.2 3.16"1.7 3.67"2.3
(0.71–1.75) (1.3–9.5) (1.6–7.9)
{A vs. B, -0.0001} {B vs. C, n.s.}
TfR-F-Index 0.67"0.2 1.57"0.8 2.10"1.4
(0.29–1.06) (0.43–4.71) (0.84–4.80)
{A vs. B, -0.0001} {B vs. C, n.s.}
TfR-F-Index, CRP-adjusted
wIncreased/normal, (% increased)x 0/38 (0%) 21/18 (54%) 6/4 (60%)
The values are mean"SD (and range). Values in square brackets are reference values, values in curly brackets are p-values;
amean maximal lymph node size in cm; n.s., non-significant. Hb, hemoglobin; WBC, white blood cell; sTfR, soluble transferrin
receptor; TfR-F-Index, sTfR/log ferritin ratio; CRP, C-reactive protein; SD, standard deviation.
The mean sTfR concentration in Binet C patients
was significantly increased when compared to Binet
A patients (3.67"2.3 mg/L, range1.6–7.9, p-0.0001),
but did not significantly differ compared to Binet B.
Individual sTfR concentrations were increased in eight
of 10 (80%) Binet C individuals.
The mean TfR-F-Index was significantly higher
compared to Binet A (2.10"1.4; range 0.84–4.80,
p-0.0001) and did not differ compared to Binet B
patients. Five patients (50%) of the Binet C group
showed a TfR-F-Index above 1.5. Six Binet C patients
(60%) showed an abnormal CRP-adjusted TfR-F-Index.
There were no significant differences between the
Binet stages with respect to ferritin concentration and
transferrin saturation.
Considering all 87 enrolled CLL patients, the sTfR
concentration was above the upper reference limit of
1.75 mg/L in 41 (47%) patients. The TfR-F-Index, with
a threshold value of 1.5, was increased in 23 (26%)
individuals, and the CRP-adjusted TfR-F-Index was
abnormal in 27 (31%) patients.
When considering patients with three or more
lymph node regions having significant tumor mass,
45 patients were affected (Binet A, ns0; Binet B,
ns39; Binet C, ns6). sTfR was increased in 38/45
patients, the TfR-F-Index in 23/45 patients and the
CRP-adjusted TfR-F-Index in 25/45 patients. Thus, the
diagnostic accuracy for the detection of significant
tumor load by an increased sTfR, TfR-F-Index and
CRP-adjusted TfR-F-Index in CLL patients was 89%,
74% and 75%, with a sensitivity of 84%, 51% and 56%
and a specificity of 93%, 98% and 95%, respectively.
In CLL patients with anemia (Binet A, ns4; Binet B,
ns11; Binet C, ns5), showing a Hb level -130
g/L in men and -120 g/L in women, the sTfR was
increased in 14 patients (70%), and the TfR-F-Index
was increased in seven patients (35%). Considering
the cut-off value of 0.8 for patients with a CRP )5
mg/L, the CRP-adjusted TfR-F-Index was increased in
nine of 20 patients (45%). No significant differences
in sTfR and the TfR-F-Index were observed between
patients with and without anemia.
1294 Metzgeroth et al.: TfR-F-Index in CLL
Article in press - uncorrected proof
Figure 1 Individual TfR-F-Index and mean TfR-F-Index (——)
for all CLL patients, subdivided according to their Binet
stage.
All Binet A patients had a normal TfR-F-Index. In Binet B
patients, the mean TfR-F-Index was significantly increased
(p-0.0001), the further increase in Binet C patients was not
significant. The dotted line represents the threshold value of
1.5 indicating the onset of ID in patients with a CRP value
below 5 mg/L. The empty marks represent the 20 anemic
patients (Hb in females -120 g/L, in males -130 g/L).
Figure 2 Individual TfR-F-Index time courses for 12 patients,
responding to a fludarabine-based regime that was given
every 4 weeks.
In these responders, the application of the fludarabine-based
therapy was accompanied by a continuous decline in the
TfR-F-Index, which normalized in 11 patients who achieved
complete remission. The decline began immediately after
initiation of treatment, and was statistically significant after
the second course of therapy (ps0.002).
Twelve individuals received up to six cycles (mean
4, range 4–6) of fludarabine-based therapy. All res-
ponded to treatment with complete hematological
remission and partial or complete disappearance of
lymph node enlargement. All these patients had an
increased TfR-F-Index and an increased sTfR serum
concentration before the initiation of treatment.
The high pre-treatment sTfR values (7.18"2.1 mg/L,
range 4.3–9.5) and TfR-F-Index (4.09"2.0, range
2.2–9.5) progressively declined to near normal values
following four cycles of therapy (mean TfR-F-Index
1.02"0.3, range 0.5–1.7, p-0.0001, and mean sTfR
2.10"1.0 mg/L, range 1.2–4.7, p-0.0001, respective-
ly), as shown in Figure 2.
The decline of the TfR-F-Index in responders began
immediately following the start of therapy and was
statistically significant compared to pre-treatment
values after the second course of the treatment (4.09
vs. 2.13, ps0.002). The decrease continued during the
following courses, reaching normal TfR-F-Index by
the end of therapy in all 11 patients with complete
clinical remission. The remaining patient achieved
only partial remission after four cycles of chemother-
apy, and the TfR-F-Index remained increased with an
end of treatment value of 1.69 (Figure 2).
Discussion
Our current data suggest that calculation of the TfR-
F-Index does not increase the reliability of the sTfR
concentration in the assessment of iron status in
patients with CLL. Similar to sTfR, the TfR-F-Index
depends on tumor load, and shows increased values
in advanced CLL despite the lack of ID or increased
erythropoesis.
The TfR-F-Index was introduced to increase the
diagnostic sensitivity and specificity of sTfR in the
assessment of ID (3, 7, 10–13). There are several rea-
sons for the diagnostic improvement of sTfR for
detecting ID using determination of the TfR-F-Index.
The increased sensitivity is based on the ability of
ferritin to detect deficiencies in storage iron, whereas
the sTfR concentration only increases when the iron
available for erythropoesis becomes insufficient. Fer-
ritin also contributes to the higher specificity of the
TfR-F-Index in comparison to single determinations of
sTfR alone, by amplifying the influence of ID and
attenuating the ‘‘erythropoesis part’’ of the sTfR con-
centration. Thus, there was a legitimate hope to
exclude or minimize the influence of tumor burden
on the sTfR concentration in patients with CLL by
combining sTfR and ferritin through the use of the
TfR-F-Index.
When compared with sTfR, which was increased in
nearly half of the patients, about one quarter of the
individuals showed an increased TfR-F-Index at diag-
nosis. These results show that calculation of the TfR-
F-Index reduces the influence of tumor load in CLL
patients when compared to determination of sTfR
concentrations alone. Although the difference was
statistically significant (ps0.01), a 26% false positive
rate is not a sound base for detection of ID in these
individuals. However, it should be mentioned that
increased concentrations of sTfR and the TfR-F-Index
were restricted to Binet B and C patients. The sTfR
concentration and the TfR-F-Index were normal in all
Binet A individuals.
To reduce the influence of inflammation on the
acute phase reactant ferritin, an interpretation of the
TfR-F-Index based on CRP concentration has been
proposed (3, 7, 10–13). The application of this strategy
using the CRP-adjusted TfR-F-Index did not improve
the results in our study, and even seemed to impair
its value. Considering the CRP-adjusted threshold, the
number of patients with increased TfR-F-values
increased from 23 (26%) to 27 (31%). With this para-
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meter as well, increased values were restricted to CLL
patients staged as Binet B or C.
There is no doubt that the observed increase in the
TfR-F-Index in patients with CLL – similar to the
increase in the sTfR concentration – is the result of
high tumor burden. ID and increased erythropoesis
were carefully excluded. In all cases, ferritin values
were above the lower limit of normal, there was no
significant difference in mean ferritin concentrations
between the Binet stages and there was detectable
storage iron in the bone marrow. The dependence of
sTfR and TfR-F-Index on tumor burden is evident with
the strong correlation between these parameters and
Binet classification, which is primarily determined by
tumor load. Patients with low tumor burden and ful-
filling the Binet A criteria had, without exception, a
TfR-F-Index below the threshold value. However, the
mean TfR-F-Index was increased when compared to
normal individuals.
The increase in tumor load in Binet B and C patients
was accompanied by a significant increase in the
mean TfR-F-Index and sTfR concentrations. The pro-
portion of patients with increased TfR-F-Index incre-
ased from 0% in Binet A to 46% (18/39) in Binet B, and
50% (5/10) in Binet C patients. However, the increase
compared between Binet B and C was not statistically
significant. This finding is not surprising taking into
account that Binet C stage is primarily defined by
hematological insufficiency, and depends on the
tumor load indirectly only.
Similar to sTfR concentrations, the TfR-F-Index did
not show only excellent correlation with tumor bur-
den at the time of diagnosis, but also within the
course of the disease during therapy. In the 12
patients responding to therapy, all but one patient
achieved a normal TfR-F-Index (Figure 2), which was
accompanied by significant regression or even dis-
appearance in the lymph nodes. Complete remission
was always associated with complete normalization
of the TfR-F-Index. These findings further support the
close association between the TfR-F-Index and tumor
mass in CLL.
One may argue that sTfR and the TfR-F-Index are
reliable tests for iron in Binet A patients, as both para-
meters were within the normal range in this group.
The same could be proposed for patients who achieve
complete remission, which was always accompanied
by complete normalization of sTfR and the TfR-F-
Index. However, one should be aware that in cases of
CLL relapse or disease progression, both parameters
increase due to increasing tumor mass (9). This is of
particular importance as it was demonstrated that
increasing sTfR precedes visible lymph node enlarge-
ment by 1–4 months (9). Based on this aspect, the
differentiation between ID and disease progression
by measurement of these two parameters would be
impossible.
In summary, our data demonstrate that the TfR-F-
Index, similar to the sTfR serum concentration, is
closely associated with tumor load at diagnosis and
during the course of the disease in patients with CLL.
Therefore, use of these parameters is not appropriate
for screening of ID in this patient group.
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